Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone954-541-8000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$40,000.00
Profitability
Miscellaneous
Employees44
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Motus GI (NASDAQ:MOTS) Frequently Asked Questions
What is Motus GI's stock symbol?
Motus GI trades on the NASDAQ under the ticker symbol "MOTS."
How were Motus GI's earnings last quarter?
Motus GI Holdings Inc (NASDAQ:MOTS) released its quarterly earnings data on Friday, August, 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. View Motus GI's Earnings History.
When is Motus GI's next earnings date?
What price target have analysts set for MOTS?
2 brokerages have issued 12-month price objectives for Motus GI's shares. Their forecasts range from $6.00 to $10.00. On average, they anticipate Motus GI's stock price to reach $7.67 in the next year. This suggests a possible upside of 364.6% from the stock's current price. View Analyst Price Targets for Motus GI.
What is the consensus analysts' recommendation for Motus GI?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Motus GI in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Motus GI.
Has Motus GI been receiving favorable news coverage?
News coverage about MOTS stock has trended somewhat negative this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Motus GI earned a news impact score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Motus GI.
Are investors shorting Motus GI?
Motus GI saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,180,000 shares, an increase of 12.4% from the August 30th total of 1,050,000 shares. Based on an average daily trading volume, of 87,600 shares, the short-interest ratio is currently 13.5 days. Currently, 5.5% of the company's stock are sold short. View Motus GI's Current Options Chain.
Who are some of Motus GI's key competitors?
Some companies that are related to Motus GI include Vapotherm (VAPO), Neuronetics (STIM), Repro-Med Systems (REPR), Cytosorbents (CTSO), RenovaCare (RCAR), iCAD (ICAD), T2 Biosystems (TTOO), BRAINSWAY LTD/S (BWAY), Sensus Healthcare (SRTS), Liquidia Technologies (LQDA), Spectral Medical (EDTXF), Nephros (NEPH), Endologix (ELGX), Apollo Endosurgery (APEN) and STRATA Skin Sciences (SSKN).
What other stocks do shareholders of Motus GI own?
Who are Motus GI's key executives?
Motus GI's management team includes the folowing people:
- Mr. Timothy P. Moran, CEO & Director (Age 47)
- Mr. Mark Pomeranz, Pres, COO & Director (Age 58)
- Mr. Andrew Lawrence Taylor, Chief Financial Officer (Age 48)
When did Motus GI IPO?
(MOTS) raised $21 million in an initial public offering on Wednesday, February 14th 2018. The company issued 3,500,000 shares at $5.00-$7.00 per share. Piper Jaffray acted as the underwriter for the IPO and Oppenheimer & Co. was co-manager.
How do I buy shares of Motus GI?
Shares of MOTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Motus GI's stock price today?
One share of MOTS stock can currently be purchased for approximately $1.65.
How big of a company is Motus GI?
Motus GI has a market capitalization of $47.45 million and generates $40,000.00 in revenue each year. The company earns $-22,260,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Motus GI employs 44 workers across the globe.View Additional Information About Motus GI.
What is Motus GI's official website?
How can I contact Motus GI?
Motus GI's mailing address is 1301 EAST BROWARD BOULEVARD 3rd Floor, FT. LAUDERDALE FL, 33301. The company can be reached via phone at 954-541-8000 or via email at [email protected]
MarketBeat Community Rating for Motus GI (NASDAQ MOTS)
MarketBeat's community ratings are surveys of what our community members think about Motus GI and other stocks. Vote "Outperform" if you believe MOTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
